公告称，先天性心脏病封堵器产品的销售收入是集团收入的重要组成部分，由截至2024年6月30日止六 个月的1.29亿元增加24.9%至截至2025年6月30日止六个月的1.61亿元，分别占集团同期收入的51.6%及 48.7%。先天性心脏病封堵器产品的销售收入能够实现较快增长，主要由于集团的传统金属封堵器产品 收入稳健增长的同时，集团的第四代MemoSorb生物可降解室间隔封堵器和房间隔缺损封堵器顺利获证 并快速实现商业化后，带来了可观的增量收入，同时集团也正在通过可降解技术实现产品迭代和产品差 异化竞争格局。 心泰医疗(02291)发布截至2025年6月30日止六个月的中期业绩，营业总收入3.3亿元(人民币，下同)，同 比增加32.36%;归母净利润1.82亿元，同比增加29.81%;每股基本盈利0.5249元。 ...

公告称，先天性心脏病封堵器产品的销售收入是集团收入的重要组成部分，由截至2024年6月30日止六 个月的1.29亿元增加24.9%至截至2025年6月30日止六个月的1.61亿元，分别占集团同期收入的51.6%及 48.7%。先天性心脏病封堵器产品的销售收入能够实现较快增长，主要由于集团的传统金属封堵器产品 收入稳健增长的同时，集团的第四代MemoSorb®生物可降解室间隔封堵器和房间隔缺损封堵器顺利获 证并快速实现商业化后，带来了可观的增量收入，同时集团也正在通过可降解技术实现产品迭代和产品 差异化竞争格局。 智通财经APP讯，心泰医疗(02291)发布截至2025年6月30日止六个月的中期业绩，营业总收入3.3亿元 (人民币，下同)，同比增加32.36%;归母净利润1.82亿元，同比增加29.81%;每股基本盈利0.5249元。 ...

消息上，为支持药品和医疗器械创新发展，国家医保局日前制定新上市药品首发价格机制，新增了100 多项与医疗新技术相关的价格项目，促进高端医疗设备的临床转化应用。 中信建投研报称，港股医疗器械公司整体创新性较强，多家企业即将步入扭亏为盈或业绩快速释放的阶 段。今年以来，有创新产品上市、技术突破实现license-out可能的催化，以及账上现金丰富、业绩快速 释放、估值低位的部分18A器械公司，年初至今有翻倍以上的涨幅；部分业绩高增长的低估值龙头器械 公司年初至今亦有较好表现。(格隆汇) 心泰医疗(2291.HK)盘中一度涨近8%，高见27.4港元创4月底以来新高，近一个月累计升幅达30%，总市 值93亿港元。 公司是稳健盈利的港股创新医疗器械企业。根据弗若斯特沙利文统计，就2021年的销售收入而言，心泰 医疗是中国最大的先天性心脏病封堵器制造商（市场份额为38%）。 ...

Core Viewpoint - The company, Xianjian Technology, reported a slight increase in revenue for 2024, but a significant decline in operating profit and net profit attributable to shareholders, indicating challenges in maintaining profitability despite revenue growth [2][3]. Financial Performance - Revenue for 2024 reached approximately RMB 1.304 billion, reflecting a year-on-year growth of about 2.9% [2][3]. - Gross profit was approximately RMB 981.4 million, showing a decrease of 1.4% compared to the previous year [2]. - Operating profit fell sharply by 51.4% to RMB 186.3 million [2]. - Profit before tax increased by 13.3% to RMB 199.0 million [2]. - Net profit attributable to shareholders was approximately RMB 222.4 million, down 15.5% from the previous year [2]. - Basic earnings per share decreased by 15.0% to RMB 0.051 [2]. Business Drivers - Xianjian Technology, established in 1999 and listed in 2011, focuses on the R&D, production, and sales of cardiovascular and peripheral vascular interventional medical devices [4]. - The company has a strong patent portfolio with 2,198 patents and 15 products approved for the "Special Review Procedure for Innovative Medical Devices" by the National Medical Products Administration (NMPA) [4]. Innovation and Market Expansion - R&D investment for 2024 was approximately RMB 303 million, aimed at driving technological innovation and product upgrades [5]. - Overseas sales reached approximately RMB 347 million, marking a year-on-year growth of 26.0%, with significant growth in Asia (excluding mainland China) and Europe [5]. - Domestic sales amounted to approximately RMB 957 million, accounting for 73.4% of total revenue, maintaining a leading market share [5]. Product Segmentation - Structural heart disease business generated sales of approximately RMB 528 million, up 6.4% year-on-year [8]. - Peripheral vascular business contributed approximately RMB 751 million in revenue, an increase of 6.2% [8]. - Cardiac pacing and electrophysiology business achieved sales of approximately RMB 25 million [8].